Tovar-Vázquez FE, Guillén-Cazarín EH

Language: Spanish
References: 16
Page: 57-62
PDF size: 102.78 Kb.

ABSTRACT

Since the sudden sensorineural hearing loss (SSNHL) was described for the first time by McCabe (1979), many have tried to define, explain and handle this upheaval correctly. The SSNHL is considered an otologic emergency that requires immediate intervention. In agreement with recent reports, USA has an annual incidence of SSNHL of 5- 20 cases by each 100 000 inhabitants. Although the diagnosis of this entity is not complicated, it is difficult to establish an effective and standardized handling because its etiology is not known with certainty. By such reason, the present study was made in order to review the actual treatment, the recent studies and the new modalities of handling of this pathology. English literature of 1997 to 2004 was reviewed, in search of relevant studies, controlled, randomized and prospective, in humans and animal models, with special approach in physiopathology and treatment advances. Recent results in use of antivirals, systemic and intratympanic steroids, alone and combined, and the safety of its use, vasodilator hemorreaologic, immunosuppresors, prostanoids, magnesium, carbogen, relation between HLA and SSNHL and prognosis, association with serum antiendothelial cell antibodies were examined. Conclusions are that the results are promising with individualized therapeutic options, that are letting to be empiric, even though there is the need of a consense in management of this pathology.

REFERENCES

1. Eisenman D, Arts HA. Effectiveness of treatment for sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2000; 126 (9): 1161-4.

2. Haberkamp TJ, Tanyeri HM. Management of idiopathic sudden sensorineural hearing loss. Am J Otol 1999; 20 (5): 587-92.

3. Ducket LG. Sudden hearing loss. En: Meyerhoff WL (ed.). Diagnosis and management of hearing loss. Saunders, Philadelphia, 1980; pp. 12-22.

4. Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977; 86 (4 Pt 1): 463-80.

5. Yeo SW, Park SN, Park YS, et al. Different distribution of HLA class II alleles according to response to corticosteroid therapy in sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 2001; 127 (8): 945-9.

6. Ogawa K, Takei S, Inoue Y, Kanzaki J. Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: a doubleblinded clinical study. Otol Neurotol 2002; 23 (5): 665-8.

7. Ohlsen KA, Didier A, Baldwin D, et al. Cochlear blood flow in response to dilating agents. Hear Res 1992; 58 (1): 19-25.

8. Uri N, Doweck I, Cohen-Kerem R, Greenberg E. Acyclovir loss. Otolaryngol Head Neck Surg 2003; 128 (4): 544-9.

9. Tucci DL, Farmer JC Jr, Kitch RD, Witsell DL. Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otol Neurotol 2002; 23 (3): 301-8.

10. Kopke RD, Hoffer ME, Wester D, et al. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol 2001; 22 (4): 475-9.

11. 11.Alexiou C, Arnold W, Fauser C, et al. Sudden sensorineural hearing loss: does application of glucocorticoids make sense? Arch Otolaryngol Head Neck Surg 2001; 127 (3): 253-8.

12. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999; 109 (7 Pt 2): 1-17.

13. Blakley BW. Clinical forum: a review of intratympanic therapy. Am J Otol 1997; 18 (4): 520-6.

14. Yang GS, Song HT, Keithley EM, Harris JP. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. Am J Otol 2000; 21 (4): 499-

16. Gordin A, Goldenberg D, Golz A, et al. Magnesium: a new therapy for idiopathic sudden sensorineural hearing loss. Otol Neurotol 2002; 23 (4): 447-51.